Cite
HARVARD Citation
Weinstock-Guttman, B. et al. (2022). Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple sclerosis. pp. 790-800. [Online].